AwesomeCapital
Search This Blog
Sunday, December 9, 2018
Baird Positive on Sarepta (SRPT) as Pivotal Design Gets Posted
Baird analyst Brian Skorney weighed in on Sarepta Therapeutics (NASDAQ: SRPT), noting a pivotal design gets posted to clinicaltrials.gov.
https://www.streetinsider.com/Analyst+Comments/Baird+Positive+on+Sarepta+%28SRPT%29+as+Pivotal+Design+Gets+Posted/14901457.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.
Newer Post
Older Post
Home
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.